<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        65-539-14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        GABIN 400MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        GABAPENTIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        400
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        170.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DEEF PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DEEF PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 479]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            DEEF MARKITING COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DEEF PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>GABIN</strong> belongs to a group of medicines used to treat epilepsy and peripheral neuropathic pain (long lasting pain caused by damage to the nerves).</p><p>The active ingredient in<strong> GABIN</strong> is gabapentin.</p><p><strong>GABIN</strong> is used to treat</p><p>&middot; Various forms of epilepsy (seizures that are initially limited to certain parts of the brain, whether the seizure spreads to other parts of the brain or not). Your doctor will prescribe <strong>GABIN</strong> for you to help treat your epilepsy when your current treatment is not fully controlling your condition. You should take <strong>GABIN</strong> in addition to your current treatment unless told otherwise. <strong>GABIN</strong> can also be used on its own to treat adults and children over 12years of age.</p><p>&middot; Peripheral neuropathic pain (long lasting pain caused by damage to the nerves). A variety of different diseases can cause peripheral neuropathic pain (primarily occurring in the legs and/or arms), such as diabetes or shingles.</p><p>Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles etc.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>A-Do not takes GABIN</strong></p><p>If you are allergic to gabapentin or to any of the other ingredients of this product.</p><p><strong>B-Take special care with GABIN</strong></p><p>&middot; if you suffer from kidney problems your doctor may prescribe a different dosing schedule</p><p>&middot; if you are on haemodialysis (to remove waste products because of kidney failure), tell your doctor if you develop muscle pain and/or weakness</p><p>&middot; if you develop signs such as persistent stomach pain, feeling sick and being sick contact your doctor immediately as these may be symptoms of acute pancreatitis (an inflamed pancreas)</p><p>A small number of people being treated with anti-epileptics such as gabapentin have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</p><p><strong>Important information about potentially serious reactions</strong></p><p>A small number of people taking gabapentin get an allergic reaction or potentially serious skin reaction, which may develop into more serious problems if they are not treated. You need to know the symptoms to look out for while you are taking gabapentin<strong>.</strong></p><p>&nbsp;</p><p><strong>C-Taking other medicines, herbal or dietary supplements</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Medicines containing morphine</strong></p><p>If you are taking any medicines containing morphine, please tell your doctor orpharmacist as morphine may increase the effect of<strong> GABIN</strong>.</p><p><strong>Antacids for indigestion</strong></p><p>If <strong>GABIN</strong> and antacids containing aluminum and magnesium are taken at the same time, absorption of <strong>GABIN</strong> from the stomach may be reduced. It is therefore recommended that <strong>GABIN</strong> is taken at the earliest two hours after taking an antacid.</p><p><strong>GABIN:</strong></p><p>- is not expected to interact with other antiepileptic drugs or the oral contraceptive pill.</p><p>- may interfere with some laboratory tests, if you require a urine test tell your doctor or hospital what you are taking.</p><p><strong>D-Taking GABIN Capsules with food and drink</strong></p><p><strong>GABIN</strong> can be taken with or without food.</p><p><strong>E-Pregnancy</strong></p><p><strong>GABIN </strong>should not be taken during pregnancy, unless you are told otherwise by your doctor. Effective contraception must be used by women of child-bearing potential.</p><p>There have been no studies specifically looking at the use of gabapentin in pregnant women, but other medications used to treat seizures have reported an increased risk of harm to the developing baby, particularly when more than one seizure medication is taken at the same time. Therefore, whenever possible, you should try to take only one seizure medication during pregnancy and only under the advice of your doctor.</p><p>Contact your physician immediately if you become pregnant, think you might be pregnant or are planning to become pregnant while taking <strong>GABIN</strong>.</p><p>Do not suddenly discontinue taking this medicine. The seizures may reappear, which could have serious consequences for you and foetus.</p><p>Ask your physician or pharmacist for advice before taking any medicine.</p><p><strong>F-Breastfeeding:</strong></p><p>Gabapentin is secreted into human milk following oral administration.</p><p>Because the effect on the nursing infant is unknown, <strong>GABIN</strong> should be used in women who are nursing only if the benefits clearly outweigh the risks.</p><p>Ask your physician or pharmacist for advice before taking any medicine.</p><p><strong>&nbsp;</strong></p><p><strong>G-Driving and using machines:</strong></p><p>Antiepileptic drugs may produce CNS-related adverse effects, including dizziness and drowsiness that could impair a patient&rsquo;s ability to drive a vehicle or operate machinery, particularly during the initial stage of therapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>GABIN</strong> exactly as your physician has told you. You should check with your physician or pharmacist if you are not sure.</p><p><strong>Dosage</strong></p><p>Your physician will determine what dose is appropriate for you.</p><p><strong>If you are an elderly patient (over 65 years of age)</strong><strong>:</strong><strong> </strong>you should take the normal dose of <strong>GABIN</strong> unless you have problems with your kidneys. Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.</p><p>Continue taking <strong>GABIN</strong> until your doctor tells you to stop.</p><p><strong>Epilepsy, the usual dose is</strong></p><p><strong>Adults and adolescents over 12 years old</strong></p><p>Your doctor will usually build up your dose gradually. The starting dose will generally be between 300 mg and 900 mg each day. Thereafter, the dose may be increased as instructed by your doctor, up to a maximum of 3600 mg each day and your doctor will tell you to take this in 3 separate doses.</p><p>&nbsp;</p><p><strong>Children aged 6 years old and older</strong></p><p>The dose to be given to your child will be decided by your doctor as it is calculated against your child&rsquo;s weight. The treatment is started with a low initial dose which is gradually increased over a period of approximately 3 days. The usual dose to control epilepsy is 25-35 mg per kg of body weight per day. It is usually given in 3 separate doses.</p><p><strong>GABIN</strong><strong> is not recommended for use in children under 6 years old.</strong></p><p>Particular groups of patients like elderly patient or those with renal failure, physician may prescribe different doses.</p><p><strong>Peripheral Neuropathic Pain, the usual dose is</strong></p><p><strong>Adults</strong></p><p>Your doctor will usually build up your dose gradually.</p><p>&nbsp;The starting dose will generally be between 300 mg and 900 mg each day. Thereafter, the dose may be increased as instructed by your doctor, up to a maximum of 3600 mg each day and your doctor will tell you to take this in 3 separate doses</p><p><strong>If you have kidney problems or are receiving haemodialysis</strong></p><p>Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys or are undergoing haemodialysis.</p><p><strong>GABIN is not recommended for use in children below 6 years of age.</strong></p><p><strong>Route of administration</strong></p><p><strong>GABIN</strong> is taken orally.</p><p><strong>Duration of treatment</strong></p><p>Continue taking <strong>GABIN </strong>until your physician tells you to stop. You should not stop taking this medicine without medical advice.</p><p><strong>If you take more GABIN than you should</strong></p><p>Call your physician or go to the nearest hospital emergency unit immediately.</p><p><strong>If you forget to take GABIN</strong></p><p>If you forget to take a dose, take it as soon as you remember, unless it is time for your next dose. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking GABIN</strong></p><p>Do not stop taking <strong>GABIN</strong> unless your physician tells you to. If <strong>GABIN</strong> dose is reduced, discontinued or substituted with an alternative medication, this should be done gradually over a minimum of 1 week to minimize the risk of seizures.</p><p>Sudden stopping of <strong>GABIN</strong> may cause anxiety, insomnia, nausea, pain, sweating, irregular blood glucose level in diabetic patients which may be due to problems with the hepatic function. Additionally in clinical studies in children, aggressiveness and jerky movements were reported.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your physician or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>GABIN</strong> can cause side effects, although not everybody gets them:</p><p><strong>Contact your doctor immediately if you experience any of the following symptoms after taking this medicine as they can be serious:</strong></p><p>&middot; severe skin reactions that require immediate attention, swelling of the lips and face, skin rash and redness and/or hair loss (these may be symptoms of a serious allergic reaction)</p><p>&middot; persistent stomach pain, feeling sick and being sick as these may be symptoms of acute pancreatitis (an inflamed pancreas)</p><p>&middot; hives</p><p>&middot; fever</p><p>&middot; yellowing of your skin or of the whites of the eyes</p><p>&middot; unusual bruising or bleeding</p><p>&middot; severe fatigue or weakness</p><p>&middot; unexpected muscle pain</p><p>&middot; frequent infections</p><p>These symptoms may be the first signs of a serious reaction. A doctor should examine you to decide if you should continue taking <strong>GABIN.</strong></p><p><strong>Very common side-effects (which may affect more than 1 person in 10):</strong></p><p>&middot; Viral infection</p><p>&middot; Feeling drowsy, dizziness, lack of coordination</p><p>&middot; Feeling tired, fever</p><p><strong>Common side-effects (which may affect more than 1 person in 100)</strong></p><p>&middot; Pneumonia, respiratory infections, urinary tract infection, inflammation of the ear or other infections</p><p>&middot; Low white blood cell counts</p><p>&middot; Anorexia, increased appetite</p><p>&middot; Anger towards others, confusion, mood changes, depression, anxiety, nervousness, difficulty with thinking</p><p>&middot; Convulsions, jerky movements, difficulty with speaking, loss of memory, tremor, difficulty sleeping, headache, sensitive skin, decreased sensation (numbness), difficulty with coordination, unusual eye movement, increased, decreased or absent reflexes</p><p>&middot; Blurred vision, double vision</p><p>&middot; Vertigo</p><p>&middot; High blood pressure, flushing or dilation of blood vessels</p><p>&middot; Difficulty breathing, bronchitis, sore throat, cough, dry nose</p><p>&middot; Vomiting (being sick), nausea (feeling sick), problems with teeth, inflamed gums,</p><p>diarrhoea, stomach pain, indigestion, constipation, dry mouth or throat, flatulence</p><p>&middot; Facial swelling, bruises, rash, itch, acne</p><p>&middot; Joint pain, muscle pain, back pain, twitching</p><p>&middot; Difficulties with erection (impotence)</p><p>&middot; Swelling in the legs and arms, difficulty with walking, weakness, pain, feeling unwell, flu-like symptoms</p><p>&middot; Decrease in white blood cells, increase in weight</p><p>&middot; Accidental injury, fracture, abrasion</p><p>Additionally in clinical studies in children, aggressive behaviour and jerky movements were reported commonly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia</p><p><strong>Uncommon side effects (which may affect more than 1 person in a 1000)</strong></p><p>&middot; Allergic reactions such as hives</p><p>&middot; Decreased movement</p><p>&middot; Racing heartbeat</p><p>&middot; Swelling that may involve the face, trunk and limbs</p><p>&middot; Abnormal blood test results suggesting problems with the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthritis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menorrhagia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aphasia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin ulcer</p><p><strong>Since introduction to the market the following side-effects have been reported</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial Fibrillation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myocardial infarction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholelithiasis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysphagia</p><p>&middot; Decreased platelets (blood clotting cells)</p><p>&middot; Hallucinations</p><p>&middot; Problems with abnormal movements such as writhing, jerking movements and stiffness</p><p>&middot; Ringing in the ears</p><p>&middot; A group of side effects that could include swollen lymph nodes (isolated small raised lumps under the skin), fever, rash, and inflammation of liver occurring together</p><p>&middot; Yellowing of the skin and eyes (jaundice), inflammation of the liver</p><p>&middot; Acute kidney failure, incontinence</p><p>&middot; Increased breast tissue, breast enlargement</p><p>&middot; Adverse events following the abrupt discontinuation of gabapentin (anxiety, difficulty sleeping, feeling sick, pain, sweating), chest pain,</p><p>&middot; Blood glucose fluctuations in patients with diabetes</p><p>&middot; Breakdown of muscle fibers (rhabdomyolysis)</p><p>&middot; Change in blood test results (creatine phosphokinase increased)</p><p>&nbsp;</p><p><strong>Neuropsychiatric Adverse Events-Pediatric Patients 3-12 years of age</strong></p><p>&nbsp;</p><p>Gabapentin use in pediatric patients with epilepsy 3-12 years of age is associated with the occurrence of central nervous system related adverse events. The most significant of these can be classified into the following categories:</p><p>1) Emotional lability (primarily behavioral problems),</p><p>2) Hostility, including aggressive behaviors,</p><p>3) Thought disorder, including concentration problems and change in school performance, and</p><p>4) Hyperkinesia (primarily restlessness and hyperactivity). Among the gabapentin-treated patients, most of the events were mild to moderate in intensity.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Sudde</strong><strong>n and Unexplained Death in Patients with Epilepsy</strong></p><p>During the course of premarketing development of Gabapentin, 8 sudden and unexplained deaths were recorded among a cohort of 2203 patients treated (2103 patient-years of exposure).</p><p>&nbsp;</p><p>Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0038 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving Gabapentin (ranging from 0.0005 for the general population of epileptics to 0.003 for a clinical trial population similar to that in the Gabapentin program, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or raise further concern depends on comparability of the populations reported upon to the Gabapentin cohort and the accuracy of the estimates provided.</p><p>&nbsp;</p><p><strong>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan hypersensitivity</strong></p><p>&nbsp;</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including Gabapentin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved.</p><p>&nbsp;</p><p>It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Gabapentin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.</p><p dir="RTL">&nbsp;</p><p><strong>DRU</strong><strong>G ABUSE AND DEPENDENCE</strong></p><p>&nbsp;</p><p><strong>Controlled Substance</strong></p><p>&nbsp;</p><p>Gabapentin is not a scheduled drug.</p><p>&nbsp;</p><p><strong>Abuse</strong></p><p>&nbsp;</p><p>Gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. A small number of postmarketing cases report gabapentin misuse and abuse. These individuals were taking higher than recommended doses of gabapentin for unapproved uses. Most of the individuals described in these reports had a history of poly- substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. When prescribing gabapentin carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g. development of tolerance, self- dose escalation, and drug-seeking behavior).</p><p>&nbsp;</p><p><strong>Dependence</strong></p><p>&nbsp;</p><p>There are rare postmarketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. Such symptoms included agitation, disorientation and confusion after suddenly discontinuing gabapentin that resolved after restarting gabapentin. Most of these individuals had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. The dependence and abuse potential of gabapentin has not been evaluated in human studies.</p><p>&nbsp;</p><p><strong>If any of the side effects become serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach and sight of children.</p><p><strong>GABIN</strong> syrup: Store between 2 - 8 &deg;C in a refrigerator.</p><p>Store <strong>GABIN</strong> in the original container.</p><p>Do not use <strong>GABIN</strong> after the expiry date which is stated on the box. The expiry date refers to the last day of that month.</p><p>Do not use <strong>GABIN</strong> if you notice any visible signs of deterioration.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>GABIN</strong><strong> syrup</strong></p><p>Each 5 ml contains Gabapentin 250 mg, the other ingredients are: E211, E330, E339, E422, E952, E954, sucrose, sodium chloride, flavor and purified water.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GABIN syrup
Strawberry-flavored Colorless to pale yellow syrup.
Pack size: Bottle of 100 ml.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>DEEF Pharmaceutical Industries</p><p>Tel: 016 332 3333</p><p>Fax: 016 332 4444</p><p>E-mail: medrapv@deef.com</p><p>For any information about this medicinal product, please contact the local representative of the marketing authorization holder:</p><p>DEEF Pharmaceutical Industries</p><p>Badaye Qassim Saudi Arabia</p><p>Tel: 016 332 3333</p><p>E-mail: medrapv@deef.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                09/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمى<strong> جابين </strong>لمجموعة من الأدوية التى تستخدم فى علاج الصرع و ألم إعتلال الأعصاب الطرفية (وهو ألم يستمر لفترة طويلة نتيجة لتعرض الأعصاب للتلف).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>جابين</strong>&nbsp; يحتوي على جابابنتين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يستخدم <strong>جابين</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج الأشكال المختلفة من الصرع (التشنجات التى تقتصر الأصابة بها فى البداية على أجزاء محددة من المخ، سواء انتشرت إلى أماكن أخرى من المخ أم لا).</p><p dir="RTL">سيقوم الطبيب بوصف <strong>جابين</strong> كعلاج إضافى فى حالات الصرع الغير مسيطر عليها بالعلاج الحالى لذا يجب تناول <strong>جابين</strong> بالاضافة للعلاج الحالى ما لم يوصى الطبيب بغير ذلك.</p><p dir="RTL"><strong>جابين</strong> يمكن ان يستخدم للبالغين والاطفال&nbsp; من عمر6 سنوات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتخفيف من آلام&nbsp; إعتلال الأعصاب الطرفية(وهو ألم يستمر لفترة طويلة نتيجة لتعرض الأعصاب للتلف) والتى يتسبب فيها عدة أمراض مثل مرض السكرى وحلأ نطاقى (الحزام النارى) وعادة ما يظهر هذا الإعتلال فى الساقين واليدين ويوصف هذا الألم على أنه إحساس بالحرارة، حرقان، ألام بارقة، طعن، عقال، وجع، نخز، تنميل، دبابيس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ- موانع استعمال جابين </strong><br />إذا كنت تعانى من فرط التحسس من مادة جابابنتين أو من أي المكونات الأخرى لمستحضر<strong> جابين</strong>.<br /><strong>ب- الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال جابين</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتاج الطبيب إلى تعديل جرعات<strong> جابين</strong> إذا كنت تعانى من مشاكل بالكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك إذا كنت تقوم بعمل غسيل الكلى وخاصة إذا صاحب ذلك ألم او وهن بالعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استشر طبيبك فورا اذا كنت تعانى من ألم مستمر بالمعده، إحساس بالغثيان أو القيء(قد تكون أعراض التهاب حاد بالبنكرياس).</p><p dir="RTL">هناك عدد قليل من المرضى الذين يتناولون مضادات الصرع مثل جابابنتين قد تراودهمهم أفكار بالإنتحار أو إيذاء أنفسهم لذا يلزم مراجعة الطبيب فورا.</p><p dir="RTL"><strong>معلومة هامه عن إحتمال حدوث أعراض أعراض جانبية خطيرة</strong></p><p dir="RTL">قد يعانى عدد قليل من المرضى اللذين يتناولون جابابنتين من بعض تفاعلات التحسس الشديدة أو تفاعلات جلدية شديدة التى من الممكن أن تتحول إلى أعراض خطيرة إذا لم يتم علاجها.<strong> </strong></p><p dir="RTL"><br /><strong>ج- التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>عند تناول</strong><strong> </strong><strong>جابين مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو مكملات غذائية </strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبرالطبيب أو الصيدلي إذا كنت تتناول أو تناولت في الآونة الأخيرة أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>الأدوية التى تحتوى على المورفين.</strong></p><p dir="RTL">إذا كنت تتناول أى من الأدوية التى تحتوى على المورفين، أخبر الطبيب أو الصيدلى حيث أن المورفين يمكن أن يزيد من تأثير جابين.</p><p dir="RTL"><strong>مضادات الحموضة</strong></p><p dir="RTL">تناول<strong> &nbsp;جابين </strong>مع مضادات الحموضة التى تحتوى على الألمونيوم أو الماغنيسيوم يقلل من إمتصاص<strong> جابين. </strong>لذا يفضل أن تتناول<strong> جابين </strong>قبل مضادات الحموضة بساعتين.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناول<strong> جابين </strong>لا يتعارض مع أدوية الصرع الأخرى أو الأدوية الخاصة بمنع الحمل.</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تناول <strong>جابين </strong>قد يؤثر على نتائج بعض الفحوصات المعملية لذا يجب إخبار الطبيب قبل إجراء الفحوصات.</p><p dir="RTL"><br /><strong>د- تناول جابين مع الطعام والشراب </strong><br />يمكن تناول <strong>جابين</strong> قبل أو بعد تناول الطعام .</p><p dir="RTL"><br /><strong>ه- الحمل : </strong></p><p dir="RTL">لا يجب تناول <strong>جابين</strong> أثناء فترة الحمل ما لم يخبرك الطبيب بخلاف ذلك. يجب إتباع وسيلة فعالة لمنع الحمل.</p><p dir="RTL">لذا لايجب تناوله إلا إذا كانت الفائدة المرجوة تبرر المخاطر المحتملة على الجنين.</p><p dir="RTL">لم يتم إجراء دراسات سريرية كافية عن تاثير جابابنتين على الحمل. ولكن لوحظ حدوث مخاطر على الجنين عند تناول الأدوية الأخرى التى تعالج الصرع، وخاصة عند تناول أكثر من دواء لعلاج الصرع معا. لذا يجب تناول علاج واحد فقط لعلاج الصرع أثناء فترة الحمل وبناء على توجيهات الطبيب.<br />يوصى بالاتصال&nbsp; بالطبيب على الفور في حالة الحمل&nbsp; أوالاعتقاد&nbsp; بوجود حمل أو التخطيط للحمل أثناء تناول <strong>جابين</strong> .<br />لا توقفي الدواء فجأة أثناء الحمل فقد تعاود نوبات الصرع (التشنجات) الحدوث والتي يمكن أن يكون لها عواقب وخيمة بالنسبة لكي وللجنين.</p><p dir="RTL">اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء .<br /><br /><strong>و- الرضاعة الطبيعية : </strong><br />يفرز الجابابنتين في حليب الأم بعد تناوله عن طريق الفم . من غير المعلوم تأثير جابابنتين على الرضع لذا لا ينبغي أن يستخدم <strong>جابين</strong> من قبل النساء المرضعات إلا إذا كانت الفوائد تفوق المخاطر حيث أن التأثيرات على الرضع غير معلومة.</p><p dir="RTL">&nbsp;إسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.<br /><br /><strong>ز</strong><strong> - </strong><strong>تأثير</strong><strong>&nbsp; </strong><strong>جابين على</strong><strong> </strong><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات : </strong><br />العقاقير المضادة للصرع قد تحدث آثارا جانبية متعلقة بالجهاز العصبي المركزي&nbsp; بما في ذلك الدوار والنعاس و قد تضعف من قدرة المريض على قيادة السيارة أو تشغيل الآلات ، وخاصة أثناء المرحلة الأولى من العلاج.</p><p><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تناول <strong>جابين</strong> حسب تعليمات الطبيب المعالج , يجب أن تتحقق مع الطبيب المعالج أو الصيدلي إذا كنت غير متأكد من الجرعة . &nbsp;</p><p dir="RTL"><strong>الجرعة :</strong><br />طبيبك سوف يحدد ما هي الجرعة المناسبة لك .</p><p dir="RTL"><strong>كبار السن( اكبر من 65 سنة):</strong>يتناولون الجرعات المعتاده من <strong>جابين</strong> فى حالة ما إذا كانوا يعانون من اضطربات بالكلى، فى هذه الحالة يقوم الطبيب بتعديل الجرعات.</p><p dir="RTL">لا توقف الدواء من تلقاء نفسك حتى يخبرك الطبيب بذلك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>علاج الصرع </strong></p><p dir="RTL"><strong>البالغين والمراهقين (أكبر من 12 سنة)</strong></p><p dir="RTL">سيقوم الطبيب بزيادة الجرعة تدريجيا حتى يصل للجرعة المناسبة لحالتك. الجرعة الأولية غالبا ما تكون بين 300 ملجم إلى 900 ملجم يوميا. بعد ذلك، يمكن زيادة الجرعة حتى 3600 ملجم كجرعة قصوى يوميا مقسمة على ثلاث جرعات فى اليوم أو حسب إرشادات الطبيب.</p><p dir="RTL"><strong>الأطفال الذين تتراوح أعمارهم بين 6 سنوات فأكثر </strong></p><p dir="RTL">سيقوم الطبيب بتحديد جرعة الطفل بناء على وزن الطفل. يبدأ العلاج بجرعات صغيرة تزيد تدريجيا بصورة تصاعدية خلال فترة تقترب إلى ثلاث أيام. الجرعات المعتادة لعلاج الصرع هى 25-35 ملجم لكل كيلو جرام من وزن الجسم يوميا.يعطى الدواء عادة على ثلاث جرعات منفصلة.</p><p dir="RTL"><strong>لا ينصح باستخدام جابين في الأطفال تحت 6 سنوات . </strong></p><p dir="RTL">قد يصف الطبيب جرعات مختلفة لبعض المرضى مثل كبار السن أو المرضى الذين يعانون من مشاكل بالكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آلام&nbsp; إعتلال الأعصاب الطرفية</strong></p><p dir="RTL"><strong>البالغين والمراهقين (أكبر من 12 سنة)</strong></p><p dir="RTL">سيقوم الطبيب بزيادة الجرعة تدريجيا حتى يصل للجرعة المناسبة لحالتك. الجرعة الأولية غالبا ما تكون بين 300 ملجم إلى 900 ملجم يوميا. بعد ذلك، يمكن زيادة الجرعة حتى 3600 ملجم كجرعة قصوى يوميا مقسمة على ثلاث جرعات فى اليوم أو حسب إرشادات الطبيب.</p><p dir="RTL">قد يصف الطبيب جرعات مختلفة لبعض المرضى مثل كبار السن أو المرضى الذين يعانون من مشاكل بالكلى أو اللذين يقومون بعمليات غسيل الكلى.</p><p dir="RTL"><strong>لا ينصح باستخدام جابين في الأطفال تحت 6 سنوات. </strong></p><p dir="RTL"><br /><strong>طريقة تناول الدواء </strong><br />يتم تناول<strong> جابين</strong> عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><br /><strong>مدة العلاج </strong><br />استمر بتناول <strong>جابين</strong> حتى يخبرك طبيبك بالتوقف، يجب عدم التوقف عن تناول هذا الدواء دون استشارة طبية.</p><p dir="RTL"><br /><strong>أ- الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من جابين</strong></p><p dir="RTL">اتصل &nbsp;بالطبيب الخاص بك أو اذهب إلى أقرب مستشفى أو وحدة طوارئ على الفور.<br /><strong>ب</strong><strong> - </strong><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة جابين </strong></p><p dir="RTL">&nbsp;إذا نسيت أن تتناول جرعة تناولها حالما تتذكر، ما لم يقترب موعد الجرعة التالية. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.<br /><strong>ج</strong><strong> - </strong><strong>التوقف</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>تناول جابين </strong><br />لا تتوقف عن تناول <strong>جابين</strong> ما لم يخبرك الطبيب الخاص بك، إذا تم تخفيض جرعة <strong>جابين</strong> أو إيقافه أو استبداله&nbsp; بدواء بديل، ينبغي أن يتم ذلك تدريجياً على مدى لا يقل عن أسبوع واحد وذلك للحد من خطر النوبات العصبية.<br />وقف <strong>جابين</strong> فجأة&nbsp; قد يسبب القلق والأرق والغثيان والألم والتعرق وعدم انتظام&nbsp; مستوى السكر في الدم لدى مرضى السكري والتي قد تكون ناجمة عن مشاكل في وظائف الكبد، بالإضافة إلى ذلك تم تسجيل حالات من العدوانية والترنح الحركي&nbsp; في الدراسات السريرية على الأطفال .</p><p dir="RTL">&nbsp;إذا كان لديك أي أسئلة أخرى عن استخدام هذا المنتج، اسأل الطبيب أو الصيدلي.</p><p><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يتسبب <strong>جابين</strong> في آثار جانبية، على الرغم من أنها لا تصيب جميع من يتناول <strong>جابين</strong>.<br />أخبر الطبيب على الفور إذا كنت تواجه أي من الأعراض التالية :</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور تفاعلات على الجلد تحتاج لرعاية سريعة(تورم الوجه والشفتين، طفح جلدى، إحمرار، تساقط الشعر) فقد تكون هذه علامات لحدوث تفاعلات تحسسية شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مستمر بالمعده، إحساس بالغثيان أو القيء مماثلة لأعراض إلتهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شرى أو أرتيكاريا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصفرار الجلد والعينين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف وكدمات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالوهن والضعف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالعضلات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى المتكررة.</p><p dir="RTL">هذة الأعراض تعتبر بمثابة علامات أولى لحدوث أعراض جانبية خطيرة. لذا يجب مراجعة الطبيب فورا ليقرر إذا كنت ستستمر على تناول جابين أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة جدأ(&gt;1/10)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفيروسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالنعاس، الدوار، فقدان التناسق الحركى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى والتعب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الشائعة (&gt;1/100)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإلتهاب الرئوى وعدوى الجهاز التنفسى، إلتهاب مجرى البول، إلتهاب الاذن والإلتهابات الأخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عد الكريات البيضاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة أو زيادة الرغبة للطعام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميول عدوانية تجاه الاخرين، الإرتباك، تغير المزاج، الشعور بالاكتئاب، القلق، العصبية و صعوبة التفكير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات، تشنج الحركة، عسر التلفظ ، فقدان الذاكرة، رعاش، صعوبة النوم، صداع، تحسس الجلد، تنميل، صعوبة فى التناسق الحركى، حركة عين غير طبيعية، زيادة أو نقصان أو إنعدام رد الفعل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إزدواج الرؤية، غشاوة الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار أذنى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرتفاع ضغط الدم، التورد(الإحمرار).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس، إلتهاب القصيبات الهوائية، إحتقان الحلق، جفاف الأنف والكحه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ، غثيان،الأسهال، ألم بالمعدة، عسرالهضم، إمساك ، جفاف الحلق والفم، الإنتفاخ، ألم بالأسنان وإلتهاب اللثة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجة، الحكه، طفح، كدمات، حب الشباب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألام بالمفاصل، وجع بالعضلات، ألم بالظهر، إرتعاص عضلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف بالإنتصاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الأطراف، صعوبة فى المشى، ضعف، ألم، إحساس بالتعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص فى كريات الدم البيضاء و زيادة الوزن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرض للإصابة بحادث، سحجات، كسور كما سجلت الدراسات التى أجريت على الأطفال ميلهم للعدوانية و تشنج حركتهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع نظم القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الغير الشائعة (&gt;1/1000)</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ردود فعل تحسسية مثل شيرى.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قلة الحركة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تسارع ضربات القلب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تورم الوجه والأطراف و الجزع.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إضطراب غى نتائج تحليل الدم مما قد يوحى بحدوث مشاكل بالكبد.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>المياه الزرقاء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إلتهاب المفاصل.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>غزارة الطمث.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>فقدان القدرة على التعبير بالكلام.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الربو.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>تقرح الجلد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أعراض جانبية أخرى ظهرت بعد استخدام مادة جابابنتين على المرضى</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إرتجاف الأذينين.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إحتشاء عضلة القلب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>بطء ضربات القلب.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التحصى الصفراوى.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الإعتلال الدماغى.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>عسر البلع.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قلة عدد الصفائح الدموية (المسئولة عن تخثر الدم).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>الهلوسة.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إضطرابات فى الحركة مثل (التلوى، تشنج الحركة، التيبس).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>رنين الأذن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور مجموعة من الأعراض الجانبية التى تشتمل على تضخم الغدد الليمفاوية، الحمى، الطفح الجلدى، إلتهاب الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلس بولى، فشل كلوى حاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حجم الثدى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوقف المفاجىء عن تناول جابابنتين يتسبب فى ظهور مجموعة من الأعراض( القلق، الأرق، الغثيان، ألم، التعرق)وحدوث الأم بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إضطراب مستوى السكر بالدم مع مرضى السكرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحلل الألياف العضلية (إنحلال العضلات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير فى نتائج إختبارات الدم (زيادة فسفوكيناز الكرياتين).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأثار الجانبية المؤثرة على الحالة النفسية والعصبية فى الأطفال من عمر 3 الى 12 سنة</strong></p><p dir="RTL">استخدام جابابنتين لعلاج الصرع فى الأطفال من سن 3 الى 12 سنة يصاحبة اضطربات فى الجهاز العصبى المركزى. أهم هذه الأعراض:</p><p dir="RTL">1)&nbsp;&nbsp;&nbsp;&nbsp; عدم استقرار الحالة العاطفية(متمثلة فى اضطربات سلوكية).</p><p dir="RTL">2)&nbsp;&nbsp;&nbsp;&nbsp; العدائية تشمل (السلوكيات العدوانية).</p><p dir="RTL">3)&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الفكر تشمل(عدم القدرة على التركيز،تؤثر على التحصيل الدراسى).</p><p dir="RTL">4)&nbsp;&nbsp;&nbsp;&nbsp; فرط النشاط الحركى(زيادة الحركة و عدم الراحة).</p><p dir="RTL">معظم هذه الأعراض كانت تتراوح بين بسيطة الى متوسطة الشدة.</p><p dir="RTL"><strong>حدوث حالات الوفاة المفاجئة والغير مبررة فى المرضى اللذين يعانون من الصرع</strong></p><p dir="RTL">خلال الدراسات والأبحاث التى أجريت على مستحضر جابابنتين وذلك بعد تسويقه سجلت حدوث 8 حالات وفاة غير مبررة من بين 2203 مريض تناولو جابابنتين (خلال سنة 2013).</p><p dir="RTL">بعض هذة الحالات سجلت الوفاة ناتجة عن حدوث نوبات صرع ولكن لم يتم ملاحظة هذه النوبات مثل : النوبات النى تأتى فى الليل. وهذه تمثل نسبة 0.0038&nbsp; من حالات الوفيات خلال العام. بالرغم من أن هذا المعدل تجاوز المتوقع فى الأصحاء اللذين لهم نفس الجنس ونفس الفئة العمرية، كان هذا فى حدود المتوقع لحدوث حالات وفاة مفاجئة غير مبررة فى المرضى اللذين يعانون من الصرع ولا يستخدمون جابابنتين(تتراوح بين 0.0005من عدد المصابين بالصرع الى0.003&nbsp; لحالات مماثلة للتى تخضع للتجارب السريرية للجابابنتين و 0.005 للمرضى الذين يعانون من صرع مستعصى)</p><p dir="RTL">ونتيجة لذلك ،ما إذا كانت هذة النتائج مطمئنة أو تثير القلق تعتمد على مقارنة التقارير حول الحالات التى استخدمت جابابنتين ودقة تلك التقديرات المقدمة.</p><p dir="RTL"><strong>تفاعلات الدواء مع الإيزينوفيليا والأعراض الجماعية(</strong><strong>(DRESS</strong><strong>/فرط الحساسية لأعضاء الجسم المختلفة </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سجلت حالات تفاعلات للدواء مع الإيزينوفيليا والأعراض الجماعية(DRESS) والمعروفه أيضا بفرط حساسية أعضاء الجسم المختلفة وذلك مع المرضى الذين يتلقون علاجات الصرع بما فيهم جابابنتين بعض هذه الأعراض كانت تتسبب فى الوفاة أو تمثل خطرا علي الحياة وعادة تظهر هذه الأعراض (ولايمكن قصرها على ذلك)على:</p><p dir="RTL">حمى، طفح جلدى، &nbsp;و/أو إعتلال العقد الليمفاوية بالإضافة إلى الأعراض الجانبية التى تصيب الأعضاء الأخرى مثل:&nbsp; إلتهاب الكبد، إلتهاب الكلى، إلتهاب عضلة القلب، تغير فى صورة الدم وإلتهاب العضلات تشبه فى بعض الأحيان العدوى الفيروسية الحادة. الإيزينوفيليا غالبا ما تظهر بتداخل أكثر من عضو بالجسم فى هذه الأثار وذلك لأن هذه الأعراض تظهر فى أكثر من جزء بالجسم فقد يؤدى إلى أعراض أخرى.</p><p dir="RTL">من المهم جدا التشخيص لأعراض فرط التحسس خاصة الحمى و إعتلال العقد الليمفاوية والتى قد تكون موجودة ويكون الطفح الجلدى غير واضح. فى حالة وجود هذه الأعراض يجب تقييم حالة المريض. فى حالة لم نتمكن من تحديد السبب الرئيسى لهذه الأعراض يجب أن نوقف استخدام جابابنتين فورا.</p><p dir="RTL"><strong>فرط &nbsp;الاستخدام واعتياد للدواء</strong></p><p dir="RTL">جابابنتين ليس من الأدوية المدرجة بالجدول الخاص بالأدوية تحت الرقابة.</p><p dir="RTL"><strong>فرط الاستخدام</strong></p><p dir="RTL">جابابنتين لا يرتبط مع المستقبلات الخاصة بمستحضرات بنزوديازبين أو مستقبلات المواد الأفيونية (مستقبلات المورفين، دلتا1 ، كابا) أو مستقبلات القناب1 . سجل حدوث عدد محدود من حالات سوء أو فرط استخدام جابابنتين.</p><p dir="RTL">ولوحظ أن هذه الحالات كانت تتناول جرعات أعلى من الجرعات المقررة لمستحضر جابابنتين وبإدعاءات طبية غير مثبتة.</p><p dir="RTL">معظم هذه الحالات التى تم رصدها ثبت فرط استخدامها لأدوية أخرى أو كانت تستخدم جابابنتين بغرض تخفيف أعراض الإنسحاب من أدوية أخرى. لذا يجب أن نقيم التاريخ المرضى للمريض وما إذا كان قد تعاطى أدوية بجرعات زائدة وذلك قبل وصف جابابنتين له.</p><p dir="RTL"><strong>حالات إعتياد الدواء</strong></p><p dir="RTL">رصد بشكل نادرعند بعض المرضى ظهور أعراض انسحاب لمدد وجيزة بعد التوقف وذلك فى الحالات التى كانت تتناول جابابنتين بجرعات أعلى من الجرعات المقررة وفى إستدعاءات طبية غير مثبتة. تشتمل هذه الأعراض على: حالات الهياج ، الأضطراب و التوهان كذا الأرتباك وذلك بعد التوقف فجأة عن تناول جابابنتين ثم تزول هذه الأعراض عند تناول جابابنتين مره أخرى ولوحظ أن<strong> </strong>معظم هذة الحالات التى تم رصدها ثبت فرط استخدامها لأدوية أخرى أو كانت تستخدم جابابنتين بغرض تخفيف أعراض الإنسحاب من أدوية أخرى.</p><p dir="RTL">ان حالات فرط استخدام وإعتياد الدواء لم يتم إختبارها فى الدراسات السريرية على الإنسان.</p><p dir="RTL">إذا عانيت من زيادة حدة أي من الأثار الجانبية، أو إذا لاحظت أي آثار جانبية غير المدرجة في هذه النشرة، أخبر الطبيب أو الصيدلي .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ظروف</strong><strong> </strong><strong>تخزين جابين :</strong><br />يبقي بعيداً عن متناول وبصر الأطفال.</p><p dir="RTL"><strong>جابين</strong> شراب : يحفظ &nbsp;بين درجتي حرارة من 2 &ndash; 8 &deg; م في الثلاجة .</p><p>يجب حفظ الدواء في عبوته الأصلية .<br />لاتستخدم <strong>جابين</strong> بعد تاريخ إنتهاء الصلاحية المبين على العبوة، تاريخ الإنتهاء يشير إلى اليوم الأخير من ذلك الشهر.<br />لا تستخدم <strong>جابين</strong> إذا كنت تلاحظ وجود علامات واضحة على تلفه.<br />لا ينبغي أن يتم التخلص من&nbsp; الأدوية عن طريق مياه الصرف الصحي أو عن طريق النفايات المنزلية، اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة، ومن شأن هذه التدابير أن تساعد على حماية البيئة.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جابين</strong> شراب : كل 5 مل تحتوي على&nbsp; جابابنتين 250 ملجم.</p><p dir="RTL">الصواغات الأخرى تشمل إي211 ، إي 330 ، إي 339 ، إي 422 ، إي 952 ، إي 954 ، سكروز، كلوريد الصوديوم ، نكهة ، ماء منقى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>جابين</strong> شراب هو سائل عديم اللون إلى أصفر اللون بنكهة الفراولة.</p><p dir="RTL">عبوة تحتوي على 100 مل شراب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة ديف للصناعات الدوائية<br />هاتف :0163323333<br />فاكس : 0163324444<br />البريد الالكتروني : @deef.commedrapv<br />للحصول على أي معلومات عن هذا الدواء ، الرجاء الاتصال بصاحب الترخيص :<br />شركة ديف للصناعات الدوائية<br />البدائع-القصيم- المملكة العربية السعودية<br />هاتف : 0163323333<br />البريد الالكتروني : @deef.commedrapv<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            09/2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                GABIN 250 mg/5ml Oral solution. 


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 mL of oral solution contains 250 mg of gabapentin For the full list of excipients, see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Strawberry-flavored Colorless to pale yellow syrup.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><u>Epilepsy</u></p><p><strong>GABIN</strong> is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults and children aged 6 years and above.</p><p><strong>GABIN</strong><em> is indicated as monotherapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents aged 12 years and above.</em></p><p><u>Treatment of peripheral neuropathic pain</u></p><p><strong>GABIN</strong> is indicated for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>For oral use.</p><p><strong>GABIN</strong> can be given with or without food.</p><p>For all indications a titration scheme for the initiation of therapy is described in Table 1, which is recommended for adults and adolescents aged 12 years and above. Dosing instructions for children under 12 years of age are provided under a separate sub-heading later in this section.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Table 1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>DOSING CHART &ndash; INITIAL TITRATION</p></td></tr><tr><td style="vertical-align:top"><p>Day 1</p></td><td style="vertical-align:top"><p>Day 2</p></td><td style="vertical-align:top"><p>Day 3</p></td></tr><tr><td style="vertical-align:top"><p>300 mg once a day</p></td><td style="vertical-align:top"><p>300 mg two times a day</p></td><td style="vertical-align:top"><p>300 mg three times a day</p></td></tr></tbody></table><p><u>Discontinuation of <strong>GABIN</strong></u><strong> </strong></p><p>In accordance with current clinical practice, if <strong>GABIN</strong> has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication.</p><p><strong>Epilepsy</strong></p><p>Epilepsy typically requires long-term therapy. Dosage is determined by the treating physician according to individual tolerance and efficacy.</p><p><em>Adults and adolescents:</em></p><p>In clinical trials, the effective dosing range was 900 to 3600 mg/day. Therapy may be initiated by titrating the dose as described in Table 1 or by administering 300 mg three times a day (TID) on Day 1. Thereafter, based on individual patient response and tolerability, the dose can be further increased in 300 mg/day increments every 2-3 days up to a maximum dose of 3600 mg/day. Slower titration of <strong>GABIN</strong> dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks. Dosages up to 4800 mg/day have been well tolerated in long-term open-label clinical studies. The total daily dose should be divided in three single doses, the maximum time interval between the doses should not exceed 12 hours to prevent breakthrough convulsions.</p><p>&nbsp;</p><p><em>Children aged 6 years and above:</em></p><p>The starting dose should range from 10 to 15 mg/kg/day and the effective dose is reached by upward titration over a period of approximately three days. The effective dose of <strong>GABIN </strong>in children aged 6 years and older is 25 to 35 mg/kg/day. Dosages up to 50 mg/kg/day have been well tolerated in a long-term clinical study. The total daily dose should be divided in three single doses, the maximum time interval between doses should not exceed 12 hours.</p><p>It is not necessary to monitor gabapentin plasma concentrations to optimize <strong>GABIN</strong> therapy. Further, <strong>GABIN</strong> may be used in combination with other antiepileptic medicinal products without concern for alteration of the plasma concentrations of gabapentin or serum concentrations of other antiepileptic medicinal products.</p><p><strong>Peripheral neuropathic pain</strong></p><p><em>Adults</em></p><p>The therapy may be initiated by titrating the dose as described in Table 1. Alternatively, the starting dose is 900 mg/day given as three equally divided doses. Thereafter, based on individual patient response and tolerability, the dose can be further increased in 300 mg/day increments every 2-3 days up to a maximum dose of 3600 mg/day. Slower titration of <strong>GABIN</strong> dosage may be appropriate for individual patients. The minimum time to reach a dose of 1800 mg/day is one week, to reach 2400 mg/day is a total of 2 weeks, and to reach 3600 mg/day is a total of 3 weeks.</p><p>In the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia, efficacy and safety have not been examined in clinical studies for treatment periods longer than 5 months. If a patient requires dosing longer than 5 months for the treatment of peripheral neuropathic pain, the treating physician should assess the patient&#39;s clinical status and determine the need for additional therapy.</p><p><strong>Instruction for all areas of indication</strong></p><p>In patients with poor general health, i.e., low body weight, after organ transplantation etc., the dose should be titrated more slowly, either by using smaller dosage strengths or longer intervals between dosage increases.</p><p><u>Use in elderly patients (over 65 years of age)</u></p><p>Elderly patients may require dosage adjustment because of declining renal function with age (see Table 2). Somnolence, peripheral oedema and asthenia may be more frequent in elderly patients.</p><p><u>Use in patients with renal impairment</u></p><p>Dosage adjustment is recommended in patients with compromised renal function as described in Table 2 and/or those undergoing haemodialysis. Gabapentin 100 mg can be used to follow dosing recommendations for patients with renal insufficiency.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Table 2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dosage of <strong>GABIN</strong> in Adults Based on Renal Function</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine Clearance (ml/min)</p></td><td style="vertical-align:top"><p>Total Daily Dose<sup>a</sup> (mg/day)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;80</p></td><td style="vertical-align:top"><p>900-3600</p></td></tr><tr><td style="vertical-align:top"><p>50-79</p></td><td style="vertical-align:top"><p>600-1800</p></td></tr><tr><td style="vertical-align:top"><p>30-49</p></td><td style="vertical-align:top"><p>300-900</p></td></tr><tr><td style="vertical-align:top"><p>15-29</p></td><td style="vertical-align:top"><p>150<sup>b</sup>-600</p></td></tr><tr><td style="vertical-align:top"><p>&lt;15<sup>c</sup></p></td><td style="vertical-align:top"><p>150<sup>b</sup>-300</p></td></tr></tbody></table><p><sup>a </sup>Total daily dose should be administered as three divided doses. Reduced dosages are for patients with renal impairment (creatinine clearance &lt; 79 ml/min).</p><p><sup>b</sup> To be administered as 300 mg every other day.</p><p><sup>c </sup>For patients with creatinine clearance &lt;15 ml/min, the daily dose should be reduced in proportion to creatinine clearance (e.g., patients with a creatinine clearance of 7.5 ml/min should receive one-half the daily dose that patients with a creatinine clearance of 15 ml/min receive).</p><p><u>Use in patients undergoing haemodialysis</u></p><p>For anuric patients undergoing haemodialysis who have never received gabapentin, a loading dose of 300 to 400 mg, then 200 to 300 mg of <strong>GABIN</strong> following each 4 hours of haemodialysis, is recommended. On dialysis-free days, there should be no treatment with gabapentin.</p><p>For renally impaired patients undergoing haemodialysis, the maintenance dose of <strong>GABIN</strong> should be based on the dosing recommendations found in Table 2. In addition to the maintenance dose, an additional 200 to 300 mg dose following each 4-hour haemodialysis treatment is recommended.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Suicidal Behavior and Ideation</strong></p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomized placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for gabapentin.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>If a patient develops acute pancreatitis under treatment with Gabapentin, discontinuation of Gabapentin should be considered (see section 4.8).</p><p>Although there is no evidence of rebound seizures with Gabapentin, abrupt withdrawal of anticonvulsants in epileptic patients may precipitate status epilepticus (see section 4.2).</p><p>As with other antiepileptic medicinal products, some patients may experience an increase in seizure frequency or the onset of new types of seizures with Gabapentin.</p><p>As with other anti-epileptics, attempts to withdraw concomitant anti-epileptics in treatment refractive patients on more than one anti-epileptic, in order to reach gabapentin monotherapy have a low success rate.</p><p>Gabapentin is not considered effective against primary generalized seizures such as absences and may aggravate these seizures in some patients. Therefore, Gabapentin should be used with caution in patients with mixed seizures including absences.</p><p>No systematic studies in patients 65 years or older have been conducted with Gabapentin. In one double blind study in patients with neuropathic pain, somnolence, peripheral oedema and asthenia occurred in a somewhat higher percentage in patients aged 65 years or above, than in younger patients. Apart from these findings, clinical investigations in this age group do not indicate an adverse event profile different from that observed in younger patients.</p><p>The effects of long-term (greater than 36 weeks) gabapentin therapy on learning, intelligence, and development in children and adolescents have not been adequately studied. The benefits of prolonged therapy must therefore be weighed against the potential risks of such therapy.</p><p><strong>Neuropsychiatric Adverse Events-Pediatric Patients 3-12 years of age </strong></p><p>Gabapentin use in pediatric patients with epilepsy 3-12 years of age is associated with the occurrence of central nervous system related adverse events. The most significant of these can be classified into the following categories: 1) emotional lability (primarily behavioral problems), 2) hostility, including aggressive behaviors, 3) thought disorder, including concentration problems and change in school performance, and 4) hyperkinesia (primarily restlessness and hyperactivity). Among the gabapentin-treated patients, most of the events were mild to moderate in intensity.</p><p><strong>Sudden and Unexplained Death in Patients With Epilepsy </strong></p><p>During the course of premarketing development of Gabapentin, 8 sudden and unexplained deaths were recorded among a cohort of 2203 patients treated (2103 patient-years of exposure).</p><p>Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0038 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving Gabapentin (ranging from 0.0005 for the general population of epileptics to 0.003 for a clinical trial population similar to that in the Gabapentin program, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or raise further concern depends on comparability of the populations reported upon to the Gabapentin cohort and the accuracy of the estimates provided.</p><p><strong>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)</strong><strong> </strong><strong>/Multiorgan hypersensitivity </strong></p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including Gabapentin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved.</p><p>It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Gabapentin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.</p><p><strong>DRUG ABUSE AND DEPENDENCE </strong></p><p><strong>Abuse </strong></p><p>Gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. A small number of post marketing cases report gabapentin misuse and abuse. These individuals were taking higher than recommended doses of gabapentin for unapproved uses. Most of the individuals described in these reports had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. When prescribing gabapentin carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g. development of tolerance, self-dose escalation, and drug-seeking behavior).</p><p><strong>Dependence </strong></p><p>There are rare post marketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. Such symptoms included agitation, disorientation and confusion after suddenly discontinuing gabapentin that resolved after restarting gabapentin. Most of these individuals had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. The dependence and abuse potential of gabapentin has not been evaluated in human studies.</p><p><strong>Laboratory tests</strong></p><p>False positive readings may be obtained in the semi-quantitative determination of total urine protein by dipstick tests. It is therefore recommended to verify such a positive dipstick test result by methods based on a different analytical principle such as the Biuret method, turbidimetric or dye-binding methods, or to use these alternative methods from the beginning.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><strong>Suicidal Behavior and Ideation</strong></p><p>Suicidal ideation and behaviour have been reported in patients treated with antiepileptic agents in several indications. A meta-analysis of randomized placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for gabapentin.</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.</p><p>If a patient develops acute pancreatitis under treatment with Gabapentin, discontinuation of Gabapentin should be considered (see section 4.8).</p><p>Although there is no evidence of rebound seizures with Gabapentin, abrupt withdrawal of anticonvulsants in epileptic patients may precipitate status epilepticus (see section 4.2).</p><p>As with other antiepileptic medicinal products, some patients may experience an increase in seizure frequency or the onset of new types of seizures with Gabapentin.</p><p>As with other anti-epileptics, attempts to withdraw concomitant anti-epileptics in treatment refractive patients on more than one anti-epileptic, in order to reach gabapentin monotherapy have a low success rate.</p><p>Gabapentin is not considered effective against primary generalized seizures such as absences and may aggravate these seizures in some patients. Therefore, Gabapentin should be used with caution in patients with mixed seizures including absences.</p><p>No systematic studies in patients 65 years or older have been conducted with Gabapentin. In one double blind study in patients with neuropathic pain, somnolence, peripheral oedema and asthenia occurred in a somewhat higher percentage in patients aged 65 years or above, than in younger patients. Apart from these findings, clinical investigations in this age group do not indicate an adverse event profile different from that observed in younger patients.</p><p>The effects of long-term (greater than 36 weeks) gabapentin therapy on learning, intelligence, and development in children and adolescents have not been adequately studied. The benefits of prolonged therapy must therefore be weighed against the potential risks of such therapy.</p><p><strong>Neuropsychiatric Adverse Events-Pediatric Patients 3-12 years of age </strong></p><p>Gabapentin use in pediatric patients with epilepsy 3-12 years of age is associated with the occurrence of central nervous system related adverse events. The most significant of these can be classified into the following categories: 1) emotional lability (primarily behavioral problems), 2) hostility, including aggressive behaviors, 3) thought disorder, including concentration problems and change in school performance, and 4) hyperkinesia (primarily restlessness and hyperactivity). Among the gabapentin-treated patients, most of the events were mild to moderate in intensity.</p><p><strong>Sudden and Unexplained Death in Patients With Epilepsy </strong></p><p>During the course of premarketing development of Gabapentin, 8 sudden and unexplained deaths were recorded among a cohort of 2203 patients treated (2103 patient-years of exposure).</p><p>Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0038 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained deaths in patients with epilepsy not receiving Gabapentin (ranging from 0.0005 for the general population of epileptics to 0.003 for a clinical trial population similar to that in the Gabapentin program, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or raise further concern depends on comparability of the populations reported upon to the Gabapentin cohort and the accuracy of the estimates provided.</p><p><strong>Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)</strong><strong> </strong><strong>/Multiorgan hypersensitivity </strong></p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan hypersensitivity, has been reported in patients taking antiepileptic drugs, including Gabapentin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its expression, other organ systems not noted here may be involved.</p><p>It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Gabapentin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.</p><p><strong>DRUG ABUSE AND DEPENDENCE </strong></p><p><strong>Abuse </strong></p><p>Gabapentin does not exhibit affinity for benzodiazepine, opiate (mu, delta or kappa), or cannabinoid 1 receptor sites. A small number of post marketing cases report gabapentin misuse and abuse. These individuals were taking higher than recommended doses of gabapentin for unapproved uses. Most of the individuals described in these reports had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. When prescribing gabapentin carefully evaluate patients for a history of drug abuse and observe them for signs and symptoms of gabapentin misuse or abuse (e.g. development of tolerance, self-dose escalation, and drug-seeking behavior).</p><p><strong>Dependence </strong></p><p>There are rare post marketing reports of individuals experiencing withdrawal symptoms shortly after discontinuing higher than recommended doses of gabapentin used to treat illnesses for which the drug is not approved. Such symptoms included agitation, disorientation and confusion after suddenly discontinuing gabapentin that resolved after restarting gabapentin. Most of these individuals had a history of poly-substance abuse or used gabapentin to relieve symptoms of withdrawal from other substances. The dependence and abuse potential of gabapentin has not been evaluated in human studies.</p><p><strong>Laboratory tests</strong></p><p>False positive readings may be obtained in the semi-quantitative determination of total urine protein by dipstick tests. It is therefore recommended to verify such a positive dipstick test result by methods based on a different analytical principle such as the Biuret method, turbidimetric or dye-binding methods, or to use these alternative methods from the beginning.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><u>Risk related to epilepsy and antiepileptic medicinal products in general</u></p><p>The risk of birth defects is increased by a factor of 2 &ndash; 3 in the offspring of mothers treated with an antiepileptic medicinal product. Most frequently reported are cleft lip, cardiovascular malformations and neural tube defects. Multiple antiepileptic drug therapy may be associated with a higher risk of congenital malformations than monotherapy, therefore it is important that monotherapy is practised whenever possible. Specialist advice should be given to women who are likely to become pregnant or who are of childbearing potential and the need for antiepileptic treatment should be reviewed when a woman is planning to become pregnant. No sudden discontinuation of antiepileptic therapy should be undertaken as this may lead to breakthrough seizures, which could have serious consequences for both mother and child. Developmental delay in children of mothers with epilepsy has been observed rarely. It is not possible to differentiate if the developmental delay is caused by genetic, social factors, maternal epilepsy or the antiepileptic therapy.</p><p><u>Risk related to gabapentin</u></p><p>There are no adequate data from the use of Gabapentin in pregnant women.</p><p>Studies in animals have shown reproductive toxicity. The potential risk for humans is unknown. Gabapentin should not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the foetus.</p><p>No definite conclusion can be made as to whether gabapentin is associated with an increased risk of congenital malformations when taken during pregnancy, because of epilepsy itself and the presence of concomitant antiepileptic medicinal products during each reported pregnancy.</p><p>Gabapentin is excreted in human milk. Because the effect on the breast-fed infant is unknown, caution should be exercised when gabapentin is administered to a breast-feeding mother. Gabapentin should be used in breast-feeding mothers only if the benefits clearly outweigh the risks.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Gabapentin may have minor or moderate influence on the ability to drive and use machines Gabapentin acts on the central nervous system and may cause drowsiness, dizziness or other related symptoms. Even, if they were only of mild or moderate degree, these undesirable effects could be potentially dangerous in patients driving or operating machinery. This is especially true at the beginning of the treatment and after increase in dose.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions observed during clinical studies conducted in epilepsy (adjunctive and monotherapy) and neuropathic pain have been provided in a single list below by class and frequency (very common (&ge; 1/10); common (&ge; 1/100 to&lt; 1/10); uncommon (&ge; 1/1000 to &lt; 1/100); rare (&ge; 1/10000 to &lt; 1/1000); very rare (&lt; 1/10000).. Where an adverse reaction was seen at different frequencies in clinical studies, it was assigned to the highest frequency reported.</p><p>Additional reactions reported from post-marketing experience are included as frequency Not known (cannot be estimated from the available data) in italics in the list below.</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reactions</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>Viral infection</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pneumonia, respiratory infection, urinary tract infection, infection, otitis media</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>leucopenia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Thrombocytopenia</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>allergic reactions (e.g. urticaria<em>)</em></p></td></tr><tr><td style="vertical-align:top"><p>Not Known</p></td><td style="vertical-align:top"><p><em>hypersensitivity syndrome, a systemic reaction with a variable presentation that can include fever, rash, hepatitis, lymphadenopathy, eosinophilia, and sometimes other signs and symptoms</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>anorexia, increased appetite</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders </strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hostility, confusion and emotional lability, depression, anxiety, nervousness, thinking abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Hallucinations</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>somnolence, dizziness, ataxia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>convulsions, hyperkinesias, dysarthria, amnesia, tremor, insomnia, headache, sensations such as paresthesia, hypaesthesia, coordination abnormal, nystagmus, increased, decreased, or absent reflexes</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypokinesia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>other movement disorders (e.g. choreoathetosis, dyskinesia, dystonia)</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>visual disturbances such as amblyopia, diplopia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and Labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Tinnitus</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>palpitations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hypertension, vasodilatation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>dyspnoea, bronchitis, pharyngitis, cough, rhinitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>vomiting, nausea, dental abnormalities, gingivitis, diarrhea, abdominal pain, dyspepsia, constipation, dry mouth or throat, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Pancreatitis</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>hepatitis, jaundice</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>facial oedema, purpura most often described as bruises resulting from physical trauma, rash, pruritus, acne</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>Stevens-Johnson syndrome, angioedema, erythema multiforme, alopecia, drug rash with eosinophilia and systemic symptoms (see section 4.4) </em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>arthralgia, myalgia, back pain, twitching</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>rhabdomyolysis, myoclonus</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorder</strong></p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>acute renal failure, incontinence</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>impotence</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>breast hypertrophy, gynaecomastia</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very Common</p></td><td style="vertical-align:top"><p>fatigue, fever</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>peripheral oedema, abnormal gait, asthenia, pain, malaise, flu syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>generalized oedema</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>withdrawal reactions (mostly anxiety, insomnia, nausea, pains, sweating), chest pain. Sudden unexplained deaths have been reported where a causal relationship to treatment with gabapentin has not been established.</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>WBC (white blood cell count) decreased, weight gain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>elevated liver function tests SGOT (AST), SGPT (ALT) and bilirubin</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p><em>blood glucose fluctuations in patients with diabetes, blood creatine phosphokinase increased</em></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Injury and poisoning</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>accidental injury, fracture, abrasion</p></td></tr></tbody></table><p>Under treatment with gabapentin cases of acute pancreatitis were reported. Causality with gabapentin is unclear (see section 4.4).</p><p>In patients on haemodialysis due to end-stage renal failure, myopathy with elevated creatine kinase levels has been reported.</p><p>Respiratory tract infections, otitis media, convulsions and bronchitis were reported only in clinical studies in children. Additionally, in clinical studies in children, aggressive behaviour and hyperkinesias were reported commonly.</p><p><strong>Other undesirable effects are reported post-marketing Gabapentin: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial fibrillation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myocardial infarction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bradycardia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cataract.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysphagia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholelithiasis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sepsis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthritis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aphasia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Menorrhagia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin ulcer.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Acute, life-threatening toxicity has not been observed with Gabapentin overdoses of up to 49 grams. Symptoms of the overdoses included dizziness, double vision, slurred speech, drowsiness, lethargy and mild diarrhoea. All patients recovered fully with supportive care. Reduced absorption of Gabapentin at higher doses may limit drug absorption at the time of overdosing and, hence, minimize toxicity from overdoses.</p><p>Overdoses of Gabapentin, particularly in combination with other CNS depressant medications, may result in coma.</p><p>Although Gabapentin can be removed by haemodialysis, based on prior experience it is usually not required. However, in patients with severe renal impairment, haemodialysis may be indicated.</p><p>An oral lethal dose of gabapentin was not identified in mice and rats given doses as high as 8000 mg/kg. Signs of acute toxicity in animals included ataxia, laboured breathing, ptosis, hypoactivity, or excitation.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC code: N03AX12</p><p>The precise mechanism of action of gabapentin is not known.</p><p>Gabapentin is structurally related to the neurotransmitter GABA (gamma-aminobutyric acid) but its mechanism of action is different from that of several other active substances that interact with GABA synapses including valproate, barbiturates, benzodiazepines, GABA transaminase inhibitors, GABA uptake inhibitors, GABA agonists, and GABA prodrugs. <em>In vitro</em> studies with radiolabeled gabapentin have characterized a novel peptide binding site in rat brain tissues including neocortex and hippocampus that may relate to anticonvulsant and analgesic activity of gabapentin and its structural derivatives.</p><p>The binding site for gabapentin has been identified as the alpha<sub>2</sub>-delta subunit of voltage-gated calcium channels.</p><p>Gabapentin at relevant clinical concentrations does not bind to other common drug or neurotransmitter receptors of the brain including GABA<sub>A</sub>, GABA<sub>B</sub>, benzodiazepine, glutamate, glycine or N-methyl-d-aspartate receptors.</p><p>Gabapentin does not interact with sodium channels <em>in vitro</em> and so differs from phenytoin and carbamazepine. Gabapentin partially reduces responses to the glutamate agonist N-methyl-D-aspartate (NMDA) in some test systems <em>in vitro</em>, but only at concentrations greater than 100 &micro;M, which are not achieved <em>in vivo</em>. Gabapentin slightly reduces the release of monoamine neurotransmitters <em>in vitro</em>. Gabapentin administration to rats increases GABA turnover in several brain regions in a manner similar to valproate sodium, although in different regions of brain. The relevance of these various actions of gabapentin to the anticonvulsant effects remains to be established. In animals, gabapentin readily enters the brain and prevents seizures from maximal electroshock, from chemical convulsants including inhibitors of GABA synthesis, and in genetic models of seizures.</p><p>A clinical trial of adjunctive treatment of partial seizures in paediatric subjects, ranging in age from 3 to 12 years, showed a numerical but not statistically significant difference in the 50% responder rate in favour of the gabapentin group compared to placebo. Additional post-hoc analyses of the responder rates by age did not reveal a statistically significant effect of age, either as a continuous or dichotomous variable (age groups 3-5 and 6-12 years).</p><p>The data from this additional post-hoc analysis are summarised in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Response (&ge; 50% Improved) by Treatment and Age MITT* Population</p></td></tr><tr><td style="vertical-align:top"><p>Age Category</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Gabapentin</p></td><td style="vertical-align:top"><p>P-Value</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 6 Years Old</p></td><td style="vertical-align:top"><p>4/21 (19.0%)</p></td><td style="vertical-align:top"><p>4/17 (23.5%)</p></td><td style="vertical-align:top"><p>0.7362</p></td></tr><tr><td style="vertical-align:top"><p>6 to 12 Years Old</p></td><td style="vertical-align:top"><p>17/99 (17.2%)</p></td><td style="vertical-align:top"><p>20/96 (20.8%)</p></td><td style="vertical-align:top"><p>0.5144</p></td></tr></tbody></table><p>*The modified intent to treat population was defined as all patients randomised to study medication that also had evaluable seizure diaries available for 28 days during both the baseline and double-blind phases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><u>Absorption</u></p><p>Following oral administration, peak plasma gabapentin concentrations are observed within 2 to 3 hours. Gabapentin bioavailability is not dose proportional; i.e., as dose is increased, bioavailability decreases. Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively. Food has only a slight effect on the rate and extent of absorption of gabapentin (14% increase in AUC and Cmax).</p><p>Gabapentin pharmacokinetics are not affected by repeated administration. Although plasma gabapentin concentrations were generally between 2 &micro;g/ml and 20 &micro;g/ml in clinical studies, such concentrations were not predictive of safety or efficacy. Pharmacokinetic parameters are given in Table 6.</p><p>Table 6</p><p>Summary of gabapentin mean (%CV) steady-state pharmacokinetic parameters following every eight hours administration</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Pharmacokinetic parameter</p></td><td colspan="2" style="vertical-align:top"><p>300 mg</p><p>(N = 7)</p></td><td colspan="2" style="vertical-align:top"><p>400 mg</p><p>(N = 14)</p></td><td colspan="2" style="vertical-align:top"><p>800 mg</p><p>(N=14)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>%CV</p></td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>%CV</p></td><td style="vertical-align:top"><p>Mean</p></td><td style="vertical-align:top"><p>%CV</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max</sub> (&mu;g/ml)</p></td><td style="vertical-align:top"><p>4.02</p></td><td style="vertical-align:top"><p>(24)</p></td><td style="vertical-align:top"><p>5.74</p></td><td style="vertical-align:top"><p>(38)</p></td><td style="vertical-align:top"><p>8.71</p></td><td style="vertical-align:top"><p>(29)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>max</sub> (hr)</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>(18)</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>(54)</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>(76)</p></td></tr><tr><td style="vertical-align:top"><p>T1/2 (hr)</p></td><td style="vertical-align:top"><p>5.2</p></td><td style="vertical-align:top"><p>(12)</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>(89)</p></td><td style="vertical-align:top"><p>10.6</p></td><td style="vertical-align:top"><p>(41)</p></td></tr><tr><td style="vertical-align:top"><p>AUC (0-8) &mu;g&bull;hr/ml)</p></td><td style="vertical-align:top"><p>24.8</p></td><td style="vertical-align:top"><p>(24)</p></td><td style="vertical-align:top"><p>34.5</p></td><td style="vertical-align:top"><p>(34)</p></td><td style="vertical-align:top"><p>51.4</p></td><td style="vertical-align:top"><p>(27)</p></td></tr><tr><td style="vertical-align:top"><p>Ae% (%)</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>NA</p></td><td style="vertical-align:top"><p>47.2</p></td><td style="vertical-align:top"><p>(25)</p></td><td style="vertical-align:top"><p>34.4</p></td><td style="vertical-align:top"><p>(37)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>C<sub>max</sub> = Maximum steady state plasma concentration</p><p>t<sub>max</sub> = Time for C<sub>max</sub></p><p>T1/2 = Elimination half-life</p><p>AUC(0-8) = Steady state area under plasma concentration-time curve from time 0 to 8 hours postdose</p><p>Ae% = Percent of dose excreted unchanged into the urine from time 0 to 8 hours postdose</p><p>NA = Not available</p></td></tr></tbody></table><p><u>Distribution</u></p><p>Gabapentin is not bound to plasma proteins and has a volume of distribution equal to 57.7 litres. In patients with epilepsy, gabapentin concentrations in cerebrospinal fluid (CSF) are approximately 20% of corresponding steady-state trough plasma concentrations. Gabapentin is present in the breast milk of breast-feeding women.</p><p><u>Metabolism</u></p><p>There is no evidence of gabapentin metabolism in humans. Gabapentin does not induce hepatic mixed function oxidase enzymes responsible for drug metabolism.</p><p><u>Elimination</u></p><p>Gabapentin is eliminated unchanged solely by renal excretion. The elimination half-life of gabapentin is independent of dose and averages 5 to 7 hours.</p><p>In elderly patients, and in patients with impaired renal function, gabapentin plasma clearance is reduced. Gabapentin elimination-rate constant, plasma clearance, and renal clearance are directly proportional to creatinine clearance.</p><p>Gabapentin is removed from plasma by haemodialysis. Dosage adjustment in patients with compromised renal function or undergoing haemodialysis is recommended (see section 4.2).</p><p>Gabapentin pharmacokinetics in children were determined in 50 healthy subjects between the ages of 1 month and 12 years. In general, plasma gabapentin concentrations in children &gt; 5 years of age are similar to those in adults when dosed on a mg/kg basis.</p><p>In a pharmacokinetic study in 24 healthy paediatric subjects aged between 1 month and 48 months, an approximately 30% lower exposure (AUC), lower Cmax and higher clearance per body weight have been observed in comparison to available reported data in children older than 5 years.</p><p><u>Linearity/Non-linearity</u></p><p>Gabapentin bioavailability (fraction of dose absorbed) decreases with increasing dose which imparts non-linearity to pharmacokinetic parameters which include the bioavailability parameter (F) e.g. Ae%, CL/F, Vd/F. Elimination pharmacokinetics (pharmacokinetic parameters which do not include F such as CLr and T1/2), are best described by linear pharmacokinetics. Steady state plasma gabapentin concentrations are predictable from single-dose data.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><u>Carcinogenesis</u></p><p>Gabapentin was given in the diet to mice at 200, 600, and 2000 mg/kg/day and to rats at 250, 1000, and 2000 mg/kg/day for two years. A statistically significant increase in the incidence of pancreatic acinar cell tumors was found only in male rats at the highest dose. Peak plasma drug concentrations in rats at 2000 mg/kg/day are 10 times higher than plasma concentrations in humans given 3600 mg/day. The pancreatic acinar cell tumors in male rats are low-grade malignancies, did not affect survival, did not metastasize or invade surrounding tissue, and were similar to those seen in concurrent controls. The relevance of these pancreatic acinar cell tumors in male rats to carcinogenic risk in humans is unclear.</p><p><u>Mutagenesis</u></p><p>Gabapentin demonstrated no genotoxic potential. It was not mutagenic <em>in vitro</em> in standard assays using bacterial or mammalian cells. Gabapentin did not induce structural chromosome aberrations in mammalian cells <em>in vitro</em> or <em>in vivo</em>, and did not induce micronucleus formation in the bone marrow of hamsters.</p><p><u>Impairment of Fertility</u></p><p>No adverse effects on fertility or reproduction were observed in rats at doses up to 2000 mg/kg (approximately five times the maximum daily human dose on a mg/m<sup>2</sup> of body surface area basis).</p><p><u>Teratogenesis</u></p><p>Gabapentin did not increase the incidence of malformations, compared to controls, in the offspring of mice, rats, or rabbits at doses up to 50, 30 and 25 times respectively, the daily human dose of 3600 mg, (four, five or eight times, respectively, the human daily dose on a mg/m2 basis).</p><p>Gabapentin induced delayed ossification in the skull, vertebrae, forelimbs, and hindlimbs in rodents, indicative of fetal growth retardation. These effects occurred when pregnant mice received oral doses of 1000 or 3000 mg/kg/day during organogenesis and in rats given 500, 1000, or 2000 mg/kg prior to and during mating and throughout gestation. These doses are approximately 1 to 5 times the human dose of 3600 mg on a mg/m2 basis.</p><p>No effects were observed in pregnant mice given 500 mg/kg/day (approximately 1/2 of the daily human dose on a mg/m<sup>2</sup> basis).</p><p>An increased incidence of hydroureter and/or hydronephrosis was observed in rats given 2000 mg/kg/day in a fertility and general reproduction study, 1500 mg/kg/day in a teratology study, and 500, 1000, and 2000 mg/kg/day in a perinatal and postnatal study. The significance of these findings is unknown, but they have been associated with delayed development. These doses are also approximately 1 to 5 times the human dose of 3600 mg on a mg/m2 basis.</p><p>In a teratology study in rabbits, an increased incidence of post-implantation fetal loss, occurred in doses given 60, 300, and 1500 mg/kg/day during organogenesis. These doses are approximately 1/4 to 8 times the daily human dose of 3600 mg on a mg/m2 basis.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:97%"><tbody><tr><td><p>Excipients in <strong>Gabin</strong> Syrup are: E211, E330, E339, E422, E952, E954, sucrose, sodium chloride, flavor and purified water.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Not applicable.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                  2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;GABIN</strong> syrup: Store between 2 - 8 &deg;C in a refrigerator.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:97%"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>GABIN syrup</strong></p><p>Strawberry-flavored Colorless to pale yellow syrup.</p><p>Pack size: Bottle of 100 ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Keep out of reach of children.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 
DEEF Pharmaceutical Industries Co.
P.O Box 6, Badaye, Qassim 51951, Saudi Arabia
Manufactured by:  DEEF Pharmaceutical Industries Co., Saudi Arabia
Go to top of the page 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                09/2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>